Comparative Pharmacology
Head-to-head clinical analysis: DAPAGLIFLOZIN versus INVOKAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPAGLIFLOZIN versus INVOKAMET.
DAPAGLIFLOZIN vs INVOKAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing renal glucose reabsorption and lowering blood glucose.
INVOKAMET is a combination of canagliflozin, an SGLT2 inhibitor, and metformin, a biguanide. Canagliflozin inhibits sodium-glucose cotransporter 2 in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.
10 mg orally once daily.
Oral: Starting dose: 5 mg canagliflozin/500 mg metformin hydrochloride extended-release twice daily; titrate based on efficacy and tolerability, maximum 150 mg/1000 mg twice daily.
None Documented
None Documented
Clinical Note
moderateDapagliflozin + Gatifloxacin
"Dapagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateDapagliflozin + Rosoxacin
"Dapagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateDapagliflozin + Levofloxacin
"Dapagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateDapagliflozin + Trovafloxacin
"Dapagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.9 hours (range 10-16 hours) for dapagliflozin, supporting once-daily dosing. At steady state, effective half-life is ~23 hours due to metabolite.
Canagliflozin: 10–13 hours (multiple dosing); Metformin: 6.2 hours (plasma). Accumulation occurs in renal impairment.
Primarily renal and fecal: ~75% of dose excreted in urine (as unchanged dapagliflozin and glucuronide conjugates), ~21% in feces. Biliary elimination is negligible.
Canagliflozin (SGLT2 inhibitor): ~33% renal (1% unchanged, ~33% as glucuronide metabolites), ~52% fecal. Metformin (biguanide): 90% renal unchanged via tubular secretion.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor / Biguanide Combination